Global anti-diabetic drugs market will continue to grow in size (2022)

Global anti-diabetic drugs market will continue to grow in size (2022)

Diabetes is a common disease, the popularity of which can be said to be unknown, and the incidence of the disease has been high in the world. Diabetes has always been the focus of the pharmaceutical industry and the investment community, the core reason being the large number of people suffering from the disease, the large market capacity, and the high frequency of heavyweight products. According to relevant statistics, there are nearly 500 million diabetic patients in the world, and the prevalence rate is the highest among all countries in the world, which shows the scale of the anti-diabetic drug market.

Diabetes is a metabolic disease clinically characterized by hyperglycemia. Although it is one of the mainstream diseases recognized worldwide, its etiology and its pathogenesis are not yet fully understood.
 


From what is known about the pathogenesis, diabetes is mainly caused by either defective insulin secretion or impaired biological action of insulin or both. Chronic hyperglycemia in diabetic patients leads to chronic damage, dysfunction, and organ failure in various tissues of the body, especially in the eyes, kidneys, nerves, and blood vessels.

In the face of such a large group of patients and the pharmaceutical market, pharmaceutical manufacturers will not stand idly by. Since the first discovery of insulin in the 1920s, which ushered in a new era of diabetes treatment, the global anti-diabetic drug industry has undergone nearly a century of development and made tremendous progress.

Global Anti-diabetic Drugs Market Size

The global anti-diabetic drug market will reach $70 billion in 2020, is expected to reach $90 billion in 2025, and will grow to $110 billion by 2030. The next decade will be a decade of more intense competition among global anti-diabetic drug manufacturers and a decade of take-off for global anti-diabetic drug companies.

There are two types of anti-diabetic drugs commonly used in clinical practice, including oral drugs and injectable drugs

As far as active pharmaceutical ingredient (API) are: Semaglutide, Liraglutide, Empagliflozin, Dapagliflozin, Canagliflozin, Linagliptin. The oral drug is mainly Metformin Hydrochloride Tablets; the injectable drug is mainly insulin.

Metformin is the cornerstone drug for the treatment of diabetes, and the combination of drugs has become the mainstream means of treating diabetes.



China is the world´s largest country with diabetes, and the market for anti-diabetic drugs in China has been expanding year by year in recent years, with an average annual increase of more than 10%. China´s anti-diabetic drug market will further expand in the future due to factors such as the large population base in China, the upgrade of medical coverage, and the increased ability of patients to pay.